Overview

Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
Alcohol use disorders (AUDs) are a major problem facing our society. Their treatment is complex, and involves multiple behavioral and pharmacotherapy interventions. There are 3 approved medications for AUDs, but their efficacy for AUDs that co-exist with anxiety disorders is unknown. This study explores the effects of the medication, sustained-release quetiapine fumarate (Seroquel SR) for the treatment of alcohol dependence and co-morbid anxiety. Primary outcome measure is the amount of alcohol used. Secondary outcome measures include craving for alcohol, length of sobriety from drinking and level of anxiety with Seroquel SR.
Phase:
Phase 4
Details
Lead Sponsor:
Creighton University
Collaborator:
AstraZeneca
Treatments:
Quetiapine Fumarate